86111-47-9

Usage

Uses

Used in Pharmaceutical Industry:
Benzenemethanol, 2,6-dichloro-4-methoxyis used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
Benzenemethanol, 2,6-dichloro-4-methoxyis also utilized as an intermediate in the production of agrochemicals, where it plays a role in the synthesis of various agricultural chemicals to improve crop protection and yield.
Used as a Reagent in Organic Chemical Reactions:
Benzenemethanol, 2,6-dichloro-4-methoxyserves as a reagent in organic chemical reactions, facilitating specific transformations and syntheses in the laboratory setting.
Safety Precautions:

Upstream product

• 59606-87-0 1,3-dichloro-2-(chloromethyl)-5-methoxybenzene 
• 94278-65-6 methyl 2,6-dichloro-4-methoxybenzoate 
• 50-00-0 formaldehyd 
• 33719-74-3 3,5-dichloroanisole 
• 82772-93-8 2,6-dichloro-4-methoxy-benzaldehyde 
• 78444-52-7 2,4-dichloro-6-methoxybenzaldehyde 
• 126663-61-4 1-<(tert-butyldimethylsilyl)oxy>-3,5-dichlorobenzene 
• 591-35-5 3,5-dichlorophenol 
• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 461031-79-8 4-(benzyloxy)-2,6-dichlorobenzaldehyde 

Downstream Products

• 94278-69-0 2,6-dichloro-4-methoxybenzoic acid 
• 82772-93-8 2,6-dichloro-4-methoxy-benzaldehyde 
• 886617-10-3 1,5-dichloro-2-(chloromethyl)-3-methoxybenzene 
• 59606-87-0 1,3-dichloro-2-(chloromethyl)-5-methoxybenzene 
• 956319-21-4 2-(2,6-dichloro-4-methoxy-benzyl)-isoindole-1,3-dione 
• 956319-22-5 2,6-dichloro-4-methoxy-benzylamine hydrochloride 
• 955406-96-9 3-[2,6-Dichloro-4-(1-methyl-1H-pyrazol-4-yl)-benzyl]-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-2-one 
• 955407-60-0 3,5-Dichloro-N-isobutyl-4-[2-oxo-1-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-pyrrolidin-3-ylmethyl]-benzamide 
• 955406-24-3 C₂₇H₂₄Cl₂F₃N₃O₅S 
• 956125-91-0 (R)-4-benzyl-3-[(S)-2-(4-methoxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-one 
• 956125-90-9 (R)-3-(2,6-dichloro-4-methoxy-benzyl)-1-piperidin-1-yl-pyrrolidin-2-one hydrochloride 
• 956125-95-4 (R)-3',5'-dichloro-4'-(2-oxo-1-piperidin-1-yl-pyrrolidin-3-ylmethyl)-biphenyl-4-carboxylic acid 
• 956125-94-3 (R)-3',5'-dichloro-4'-(2-oxo-1-piperidin-1-yl-pyrrolidin-3-ylmethyl)-biphenyl-4-carboxylic acid methyl ester 
• 956125-93-2 (R)-trifluoro-methanesulfonic acid 3,5-dichloro-4-(2-oxo-1-piperidin-1-yl-pyrrolidin-3-ylmethyl)-phenyl ester 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION

The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.

Influences of Histidine-1 and Azaphenylalanine-4 on the Affinity, Anti-inflammatory, and Antiangiogenic Activities of Azapeptide Cluster of Differentiation 36 Receptor Modulators

Azapeptide analogues of growth hormone releasing peptide-6 (GHRP-6) exhibit promising affinity, selectivity, and modulator activity on the cluster of differentiation 36 receptor (CD36). For example, [A1, azaF4]- and [azaY4

GUANIDINOBENZOIC ACID COMPOUND

[Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they

CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compound

Synthesis of novel structurally simplified estrogen analogues with electron-donating groups in ring A

A library of 25 novel estrogen analogues were prepared in five to eight steps from mostly commercially available substituted anisoles via bromination, formylation, Corey-Fuchs reaction, elimination, and Sonogashira reaction. Georg Thieme Verlag Stuttgart.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: (I) having 11 -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 -HSD type 1 activity.

PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES

The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: ( I ) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds